DK0422878T3 - (2-Imidazolin-2-ylamino)tetrahydroquinoxaliner og fremgangsmåder til anvendelse af samme - Google Patents

(2-Imidazolin-2-ylamino)tetrahydroquinoxaliner og fremgangsmåder til anvendelse af samme

Info

Publication number: DK0422878T3
Authority: DK; Denmark
Prior art keywords: group; carbon atoms; alkyl radicals; radicals containing; imidazolin
Prior art date: 1989-10-12

Application number

DK90311021.1T

Other languages

English (en)

Inventor

Charles Gluchowski

Original Assignee

Allergan Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-10-12

Filing date

1990-10-09

Publication date

1994-09-05

1990-10-09 Application filed by Allergan Inc filed Critical Allergan Inc

1994-09-05 Application granted granted Critical

1994-09-05 Publication of DK0422878T3 publication Critical patent/DK0422878T3/da

Links

CBVRKFVVWACGMA-UHFFFAOYSA-N n-(4,5-dihydro-1h-imidazol-2-yl)-3,4-dihydro-2h-quinoxalin-1-amine Chemical class N1CCN=C1NN1C2=CC=CC=C2NCC1 CBVRKFVVWACGMA-UHFFFAOYSA-N 0.000 title 1
125000004432 carbon atom Chemical group C* 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 2
239000012530 fluid Substances 0.000 abstract 2
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 abstract 2
-1 2-imidazolin-2-ylamino group Chemical group 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
230000004075 alteration Effects 0.000 abstract 1
210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
230000004410 intraocular pressure Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Otolaryngology (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Cosmetics (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK90311021.1T 1989-10-12 1990-10-09 (2-Imidazolin-2-ylamino)tetrahydroquinoxaliner og fremgangsmåder til anvendelse af samme DK0422878T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/420,817 US5077292A (en)	1989-10-12	1989-10-12	(2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same

Publications (1)

Publication Number	Publication Date
DK0422878T3 true DK0422878T3 (da)	1994-09-05

Family

ID=23667965

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK90311021.1T DK0422878T3 (da)	1989-10-12	1990-10-09	(2-Imidazolin-2-ylamino)tetrahydroquinoxaliner og fremgangsmåder til anvendelse af samme

Country Status (12)

Country	Link
US (2)	US5077292A (da)
EP (1)	EP0422878B1 (da)
JP (1)	JP2971118B2 (da)
AT (1)	ATE104973T1 (da)
AU (1)	AU628666B2 (da)
CA (1)	CA2025212C (da)
DE (1)	DE69008472T2 (da)
DK (1)	DK0422878T3 (da)
ES (1)	ES2063289T3 (da)
HK (1)	HK1004266A1 (da)
IE (1)	IE65784B1 (da)
WO (1)	WO1992013855A1 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5231096A (en) *	1989-10-12	1993-07-27	Allergan, Inc.	Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5077292A (en) *	1989-10-12	1991-12-31	Allergan, Inc.	(2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5112822A (en) *	1989-10-12	1992-05-12	Allergan, Inc.	(2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5326763A (en) *	1989-10-12	1994-07-05	Allergan, Inc.	Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5198442A (en) *	1989-10-12	1993-03-30	Allergan, Inc.	(2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5021416A (en) *	1989-10-31	1991-06-04	Allergan, Inc.	Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5369128A (en) *	1993-06-21	1994-11-29	Iowa State University Research Foundation, Inc.	Method of synchronizing farrowing in swine
US6323204B1 (en) *	1993-10-13	2001-11-27	Allergan	Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
WO1995010280A1 (en) *	1993-10-13	1995-04-20	Allergan	Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
SK77396A3 (en) *	1993-12-17	1997-01-08	Procter & Gamble	6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
US5478858A (en) *	1993-12-17	1995-12-26	The Procter & Gamble Company	5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
CN1046501C (zh) *	1994-02-08	1999-11-17	阿尔康实验室公司	新型硫脲复合物及制备硝基芳基亚氨基杂环的方法
EP0775134A4 (en)	1994-08-04	1997-08-13	Synaptic Pharma Corp	NEW BENZIMIDAZOLE DERIVATIVES
US6087361A (en) *	1995-05-12	2000-07-11	Allergan Sales, Inc.	Aryl-imidazolines and aryl-imidazoles useful as α-2 adrenergic agonists without cardiovascular side effects
US6194415B1 (en)	1995-06-28	2001-02-27	Allergan Sales, Inc.	Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5856329A (en) *	1995-06-28	1999-01-05	Allergan	Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
US6495583B1 (en)	1997-03-25	2002-12-17	Synaptic Pharmaceutical Corporation	Benzimidazole derivatives
US6329369B1 (en)	1997-12-04	2001-12-11	Allergan Sales, Inc.	Methods of treating pain and other conditions
US6841684B2 (en)	1997-12-04	2005-01-11	Allergan, Inc.	Imidiazoles having reduced side effects
US7439241B2 (en) *	2003-05-27	2008-10-21	Galderma Laboratories, Inc.	Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en)	2003-05-27	2013-04-02	Galderma Laboratories Inc.	Methods and compositions for treating or preventing erythema
CA2534484A1 (en) *	2003-08-07	2005-02-17	Allergan, Inc.	Compositions for delivery of therapeutics into the eyes and methods for making and using same
RU2285003C1 (ru) *	2005-04-29	2006-10-10	Федеральное государственное унитарное предприятие "Центр по химии лекарственных средств" (ФГУП ЦХЛС-ВНИХФИ)	Способ получения 5-бром-6-[(2-имидазолин-2-ил)амино]хиноксалина l-тартрата
WO2007056457A2 (en)	2005-11-09	2007-05-18	Combinatorx, Incorporated	Methods, compositions, and kits for the treatment of medical conditions
CN101821254B (zh) *	2007-08-15	2013-10-09	阿勒根公司	肾上腺素能化合物
US20100203165A1 (en)	2008-08-01	2010-08-12	Gerald Horn	Compositions and methods for treatment of disorders or conditions of the eye
US8952011B2 (en)	2008-08-01	2015-02-10	Eye Therapies Llc	Compositions and methods for the treatment of nasal conditions
US20100197694A1 (en) *	2008-08-01	2010-08-05	Gerald Horn	Compositions and methods for treatment of diseases and conditions with increased vascular permeability
US20100202979A1 (en) *	2008-08-01	2010-08-12	Gerald Horn	Compositions and methods for treatment of pulmonary diseases and conditions
US20110003823A1 (en) *	2008-08-01	2011-01-06	Alpha Synergy Development, Inc.	Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
US12246013B2 (en)	2008-08-01	2025-03-11	Eye Therapies Llc	Vasoconstriction compositions and methods of use
US20100028266A1 (en) *	2008-08-01	2010-02-04	Alpha Synergy Development. Inc.	Composition and methods for treating allergic response
US8987270B2 (en)	2009-07-27	2015-03-24	Eye Therapies Llc	Formulations of selective alpha-2 agonists and methods of use thereof
EP2329849B1 (en)	2009-11-18	2015-04-29	Galderma Research & Development	Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) *	2009-11-19	2013-03-12	Galderma Laboratories, L.P.	Method for treating psoriasis
US8513247B2 (en)	2010-03-26	2013-08-20	Galderma Laboratories, L.P.	Methods and compositions for safe and effective treatment of erythema
MX2012010823A (es)	2010-03-26	2012-10-10	Galderma Res & Dev	Metodos y composiciones mejoradas para tratamiento seguro y efectivo de telangiectasia.
RU2571277C2 (ru)	2010-10-21	2015-12-20	Галдерма С.А.	Композиции геля с бримонидином и способы применения
US8053427B1 (en)	2010-10-21	2011-11-08	Galderma R&D SNC	Brimonidine gel composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE795970A (fr) *	1972-02-29	1973-08-27	Pfizer	Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
GB1463520A (en) *	1974-09-06	1977-02-02	Pfizer Ltd	Process for the production of imidazolines
US4908387A (en) *	1988-06-06	1990-03-13	The Regents Of The University Of California	Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis
US5077292A (en) *	1989-10-12	1991-12-31	Allergan, Inc.	(2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5112822A (en) *	1989-10-12	1992-05-12	Allergan, Inc.	(2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5021416A (en) *	1989-10-31	1991-06-04	Allergan, Inc.	Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure

1989
- 1989-10-12 US US07/420,817 patent/US5077292A/en not_active Expired - Lifetime
1990
- 1990-09-12 CA CA002025212A patent/CA2025212C/en not_active Expired - Fee Related
- 1990-10-09 DK DK90311021.1T patent/DK0422878T3/da active
- 1990-10-09 AT AT9090311021T patent/ATE104973T1/de not_active IP Right Cessation
- 1990-10-09 EP EP90311021A patent/EP0422878B1/en not_active Expired - Lifetime
- 1990-10-09 AU AU63900/90A patent/AU628666B2/en not_active Ceased
- 1990-10-09 DE DE69008472T patent/DE69008472T2/de not_active Expired - Fee Related
- 1990-10-09 ES ES90311021T patent/ES2063289T3/es not_active Expired - Lifetime
- 1990-10-11 IE IE363990A patent/IE65784B1/en not_active IP Right Cessation
- 1990-10-12 JP JP2275119A patent/JP2971118B2/ja not_active Expired - Fee Related
1991
- 1991-02-08 WO PCT/US1991/000894 patent/WO1992013855A1/en not_active Ceased
1992
- 1992-12-22 US US07/995,218 patent/US5300504A/en not_active Expired - Fee Related
1998
- 1998-04-22 HK HK98103362A patent/HK1004266A1/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU628666B2 (en)	1992-09-17
US5300504A (en)	1994-04-05
JPH03145490A (ja)	1991-06-20
CA2025212C (en)	2000-07-04
EP0422878A1 (en)	1991-04-17
DE69008472D1 (de)	1994-06-01
WO1992013855A1 (en)	1992-08-20
JP2971118B2 (ja)	1999-11-02
ES2063289T3 (es)	1995-01-01
DE69008472T2 (de)	1994-09-15
US5077292A (en)	1991-12-31
CA2025212A1 (en)	1991-04-13
IE65784B1 (en)	1995-11-15
EP0422878B1 (en)	1994-04-27
AU6390090A (en)	1991-04-18
HK1004266A1 (en)	1998-11-20
IE903639A1 (en)	1991-04-24
ATE104973T1 (de)	1994-05-15

Publication	Publication Date	Title
DK0422878T3 (da)	1994-09-05	(2-Imidazolin-2-ylamino)tetrahydroquinoxaliner og fremgangsmåder til anvendelse af samme
EP0549594A4 (en)	1993-04-16	(2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES AND METHODS OF USE THEREOF.
CA2173974A1 (en)	1995-04-20	Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
JPS5671074A (en)	1981-06-13	1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
IL96083A (en)	1997-06-10	Pharmaceutical compositions comprising (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
ATE60761T1 (de)	1991-02-15	Chinazolinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
JPS5671073A (en)	1981-06-13	Imidazole derivative
NO164350C (no)	1990-09-26	Azolylderivater, antisopp-preparater og anvendelse av forbindelsene for bekjempelse av soppinfeksjoner.
YU85001A (sh)	2004-09-03	Derivati 5-fenil-pirimidina
ATE224T1 (de)	1981-10-15	1,2-dihydro-chinolin-2-on-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel.
ES2157216T3 (es)	2001-08-16	Metodos de utilizacion de derivados de (2-imidazolin-2-ilamino) quinoxalina.
CA2149872A1 (en)	1994-06-09	Diabetes prevention and treatment
NO159794C (no)	1989-02-08	Analogifremgangsm te ved fremstilling av terapeutisk virksomme 7-substituerte theofyllinderivater.
NO923413L (no)	1992-09-01	Terapeutiske benzazepin-forbindelser
GR3020292T3 (en)	1996-09-30	Use of 2-iminothiazolidin-4-one derivatives as new medicaments
ATE24487T1 (de)	1987-01-15	Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
PT97005A (pt)	1992-09-30	Processo de prparacao de (2-imidazolin-2-ilamino)tetra-hidroquinoxalinas e de composicoes farmaceuticas que as contem
RU93005181A (ru)	1995-06-19	Производные (2-имидазолин-2-иламино)хиноксалина, лекарственная композиция и способ лечения